Citigroup Inc. set a $42.00 price objective on Mylan N.V. (NASDAQ:MYL) in a research report released on Wednesday. The firm currently has a buy rating on the stock.

Other equities analysts have also recently issued research reports about the stock. Cowen and Company restated a hold rating and set a $30.00 target price (down previously from $43.00) on shares of Mylan N.V. in a research note on Wednesday, August 9th. Royal Bank Of Canada reaffirmed a sector perform rating and set a $32.00 price target (down previously from $33.00) on shares of Mylan N.V. in a research report on Thursday, August 10th. Wells Fargo & Company set a $32.00 price target on shares of Mylan N.V. and gave the company a hold rating in a research report on Wednesday. Cantor Fitzgerald set a $34.00 price target on shares of Mylan N.V. and gave the company a hold rating in a research report on Wednesday, August 9th. Finally, Zacks Investment Research raised shares of Mylan N.V. from a sell rating to a hold rating in a research report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $41.99.

Shares of Mylan N.V. (NASDAQ MYL) opened at 38.29 on Wednesday. The stock has a market cap of $20.53 billion, a P/E ratio of 30.95 and a beta of 1.30. The company’s 50-day moving average is $32.08 and its 200-day moving average is $36.45. Mylan N.V. has a 12-month low of $29.39 and a 12-month high of $45.87.

Mylan N.V. (NASDAQ:MYL) last posted its earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.18 by ($0.08). The company had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3 billion. Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. Mylan N.V.’s revenue was up 15.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.16 EPS. On average, equities research analysts anticipate that Mylan N.V. will post $4.57 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/08/mylan-n-v-myl-pt-set-at-42-00-by-citigroup-inc.html.

A number of institutional investors have recently added to or reduced their stakes in the stock. Ardsley Advisory Partners purchased a new stake in Mylan N.V. in the 2nd quarter worth approximately $291,000. Achmea Investment Management B.V. grew its holdings in Mylan N.V. by 76.7% during the 2nd quarter. Achmea Investment Management B.V. now owns 41,018 shares of the company’s stock valued at $1,592,000 after buying an additional 17,804 shares in the last quarter. Sentry Investment Management LLC grew its holdings in Mylan N.V. by 1.1% during the 2nd quarter. Sentry Investment Management LLC now owns 34,290 shares of the company’s stock valued at $1,331,000 after buying an additional 360 shares in the last quarter. Toronto Dominion Bank grew its holdings in Mylan N.V. by 25.7% during the 2nd quarter. Toronto Dominion Bank now owns 156,074 shares of the company’s stock valued at $6,058,000 after buying an additional 31,862 shares in the last quarter. Finally, EP Wealth Advisors LLC grew its holdings in Mylan N.V. by 7.8% during the 2nd quarter. EP Wealth Advisors LLC now owns 164,340 shares of the company’s stock valued at $6,380,000 after buying an additional 11,854 shares in the last quarter. 71.97% of the stock is owned by institutional investors.

About Mylan N.V.

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan N.V. (NASDAQ:MYL)

Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.